Publications by authors named "B J Milleron"
Background: In prior randomised controlled trials, lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer mortality and overall mortality. Despite these results, organised screening in France remains a challenge. This study assessed the feasibility and efficacy of lung cancer screening within a real-life context in a French administrative territory.
View Article and Find Full Text PDFBackground: The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).
Methods: In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate.
Article Synopsis
- Molecular profiling of stage I-II non-small cell lung cancer (NSCLC) can enhance prognosis and tailor treatment approaches, focusing on the role of EGFR mutations.
- In a study of surgical NSCLC patients, a higher rate of EGFR mutations (12.9%) was observed compared to non-surgical cases, with rates reaching 27% among women.
- Despite the presence of EGFR mutations, there were no significant differences in disease recurrence or survival rates between EGFR-mutant and wild-type tumors, with a notable 5-year overall survival of 75% for resected EGFR-mutated tumors.
Background: Even after resection of early-stage non-small-cell lung cancer (NSCLC), patients have a high risk of developing recurrence and second primary lung cancer. We aimed to assess efficacy of a follow-up approach including clinic visits, chest x-rays, chest CT scans, and fibre-optic bronchoscopy versus clinical visits and chest x-rays after surgery for resectable NSCLC.
Methods: In this multicentre, open-label, randomised, phase 3 trial (IFCT-0302), patients aged 18 years or older and after complete resection of pathological stage I-IIIA NSCLC according to the sixth edition of the TNM classification were enrolled within 8 weeks of resection from 122 hospitals and tertiary centres in France.